On the other hand, the anti-tumor effect of pembrolizumab, an anti-PD-1 antibody, was not affected by the PD-L1 expression in the tumor and infiltrating immune cells [10], nor was the anti-tumor effect of nivolumab (also an anti-PD-1 antibody) affected by the PD-L1 expression in tumor cells [11]. The gene discussed is CD274; the disease is neoplasm.